Brief: Tango Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of Tng462 Plus Revolution Medicines’ Daraxonrasib
27/06/2025 12:17
June 27 (Reuters) - Tango Therapeutics Inc TNGX.O: TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF TNG462 PLUS REVOLUTION MEDICINES’ DARAXONRASIB OR ZOLDONRASIB IN PATIENTS WITH RAS-MUTANT MTAP-DELETED PANCREATIC OR LUNG CANCER TANGO THERAPEUTICS INC - TNG462 MONOTHERAPY DATA EXPECTED IN SECOND HALF OF 2025 Source text: ID:nGNX4YxcC5 Further company coverage: TNGX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,